RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced that new data from its Phase 2 Explore-CKD trial evaluating lorundrostat in patients with hypertension and chronic kidney disease (CKD) will be featured in a late-breaking clinical trials session at the American Society of Nephrology (ASN) Kidney Week 2025, taking place November 6–9 in Houston, Texas.
The late-breaking presentation, titled “Lorundrostat, a Novel Aldosterone Synthase Inhibitor (ASI), in Participants with Uncontrolled Hypertension, CKD, and Albuminuria: Results from Explore-CKD,” will be delivered by Dr. Matthew Weir, Director of the Division of Nephrology at the University of Maryland Medical Center. The presentation is scheduled for November 7 from 5:06 p.m. to 5:18 p.m. CST.
Lorundrostat is a novel aldosterone synthase inhibitor being developed as a potential therapy for patients with uncontrolled or treatment-resistant hypertension. The Explore-CKD study specifically evaluates the safety and efficacy of a 25 mg dose in participants with hypertension and comorbid CKD.
In addition to the Phase 2 data, results from Mineralys’ Phase 3 Launch-HTN trial will be featured in ASN Kidney Week’s “Best of the Journal of the American Medical Association and the New England Journal of Medicine” session on November 7. The Launch-HTN findings—previously published in JAMA—will be presented by Dr. Manish Saxena, Hypertension Specialist and Clinical Co-Director at the William Harvey Heart Centre, Barts Health NHS Trust and QMUL.
The inclusion of both trials at ASN Kidney Week underscores the growing clinical interest in lorundrostat’s potential to address unmet needs in hypertension management, particularly among patients with chronic kidney disease.
Mineralys continues to advance lorundrostat through late-stage development, positioning it as a differentiated therapy in a field where effective control of resistant hypertension remains a key challenge for clinicians.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.